PharmaGenesis London, London, UK.
Scuola Universitaria Superiore IUSS Pavia, Pavia, Italy.
Alzheimers Dement. 2023 Jun;19(6):2707-2729. doi: 10.1002/alz.12945. Epub 2023 Feb 7.
We aim to provide guidance on outcomes and measures for use in patients with Alzheimer's clinical syndrome.
A consensus group of 20 voting members nominated by 10 professional societies, and a non-voting chair, used a Delphi approach and modified GRADE criteria.
Consensus was reached on priority outcomes (n = 66), measures (n = 49) and statements (n = 37) across nine domains. A number of outcomes and measurement instruments were ranked for: Cognitive abilities; Functional abilities/dependency; Behavioural and neuropsychiatric symptoms; Patient quality of life (QoL); Caregiver QoL; Healthcare and treatment-related outcomes; Medical investigations; Disease-related life events; and Global outcomes.
This work provides indications on the domains and ideal pertinent measurement instruments that clinicians may wish to use to follow patients with cognitive impairment. More work is needed to develop instruments that are more feasible in the context of the constraints of clinical routine.
我们旨在为阿尔茨海默病临床综合征患者的结局和评估指标提供指导。
由 10 个专业学会提名的 20 名投票成员组成共识小组，以及一名非投票主席，采用德尔菲法和改良 GRADE 标准。
在九个领域中就 66 项优先结局、49 项评估指标和 37 项陈述达成了共识。一些结局和测量工具在以下方面进行了排名：认知能力；功能能力/依赖性；行为和神经精神症状；患者生活质量（QoL）；照料者生活质量；医疗保健和治疗相关结果；医学调查；疾病相关生活事件；总体结局。
这项工作为临床医生希望用于随访认知障碍患者的领域和理想的相关评估工具提供了指导。需要进一步开发更符合临床常规限制的可行性工具。
